evaluate the efficacy and safety profile of Rosuvastatin, Simvastatin and Atorvastatin in newly diagnosed type 2 diabetic patients with dyslipidaemia

Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The lipid changes associated with mellitus are attributed to increased free fatty acid flux secondary insulin resistance. This prospective, comparative, open label, randomized and parallel group. subjects enrolled this study were selected from Out-Patient Department Medicine collaboration Pharmacology, Tertiary care teaching hospital over a period month. Newly diagnosed 90 cases patients Type II Diabetes Mellitus well controlled on oral hypoglycemic drugs randomly divided into 3 groups 30 each. Group A was received Rosuvastain 10 mg O.D months, B: Simvastatin C Atrovastatin O.D. In ‘A’ mean difference Total Cholesterol between baseline versus after 6 months 82.37 mg/dl, 64.92 mg/dl 52.23 B respectively. Triglycerides 65.04 A, 39.99 37.04 C.